NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC

Inclusion Criteria

• •1. Subjects must be at least 18 years of age
• •2. Subjects must have histologically and/or cytologically confirmed NSCLC
• •3. Subjects must have incurable (advanced or metastatic) disease at the time of enrolment
• •4. Subjects must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
• •5. Subjects must provide signed informed consent prior to any study specific procedures that are not part of standard medical care.
• •6. Subjects must have measurable neoplastic disease based on the iRECIST criteria
• •7. Subjects must have received as least 1 and no more than 2 prior systemic regimens for the treatment of advanced/metastatic NSCLC. Patients are required to have progressed following treatment with both platinum-based chemotherapy and an anti-PD-(L)1 antibody administered either sequentially or concurrently. A prior PD-1/PD-L1 inhibitor is, however, not required if there was prior exposure to targeted therapies for a driver mutation positive tumors (e.g. EGFR or ALK inhibitors).